Rossari Biotech Q4 FY26 Revenue up 18%, PAT up 34%

Rossari Biotech Limited announced strong consolidated financial results for Q4 FY26, with revenue from operations growing 18% year-on-year to ₹684.9 crore and Profit After Tax (PAT) increasing 34% to ₹46.0 crore. For the full financial year FY26, revenue rose 15% to ₹2,396.4 crore and PAT was up 9% to ₹149.2 crore. EBITDA margins for Q4 and FY26 stood at 11.3% and 11.9% respectively, impacted by raw material costs. The company achieved its highest-ever quarterly revenue and EBITDA in Q4 FY26, driven by double-digit growth across all business segments. Key developments include the commissioning of an additional 15,000 MTPA ethoxylation capacity at Dahej, bringing total capacity to 66,000 MTPA, a recommended dividend of ₹0.50 per share for FY26, and the establishment of a new R&D facility in Navi Mumbai.